A study recently published in BCM Complementary and Alternative Medicine1 shows that a standardized extract of Phyllanthus emblica fruit, otherwise known as amla (Capros from Natreon Inc.; New Brunswick, NJ), supports endothelial function, oxidative stress, immune response, and lipid profile. In the randomized, double-blind, placebo-controlled trial, 59 subjects were randomly assigned to receive either 250 mg of amla, 500 mg of amla, or placebo twice daily for 12 weeks.
Results showed that when compared to baseline and placebo, both doses of amla significantly improved endothelial function, and biomarkers of oxidative stress. Specifically, the 250 mg and 500 mg doses increased nitric oxide (+41.89% and + 50.7%, respectively), glutathione (+ 24.31% and + 53.22%, respectively), and reduced Malondialdehyde (- 21.02% and - 31.44%, respectively), and the systemic inflammation biomarker, hsCRP (- 39.68% and - 53.77%, respectively). Subjects supplementing with amla also saw significant mean percent changes in total cholesterol (- 7.71%, - 11.11%), HDL-C (+ 7.33% ,+ 22.16%), LDL-C (- 11.39%, - 21.8%) and triglycerides (- 9.81%, - 19.22%), respectively with 250 mg and 500 mg twice daily. While both doses showed efficacy, the 500 mg dose was twice as effective as the 250 mg dose.
“Capros has all the attributes of being an excellent heart health product and has been consistently proven to be so in multiple clinical studies,” said Sanni Raju, PhD, CEO of Natreon, in a press release. “Capros is a totally natural and vegan edible fruit aqueous extract and when combined with its recently issued US Patent (8,962,576) on composition and methods for improving endothelial function and cardiovascular health, Capros’ solubility, stability, and taste, make it an ideal heart health product for capsule, powder, and beverage formations.”
1. Usharani P et al. “Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome: a randomised, double blind, placebo controlled clinical study.” BCM Complementary and Alternative Medicine, vol. 19 (2019): 97